Trial Profile

A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ritlecitinib (Primary) ; DTaP vaccine; Meningococcal vaccine groups A B C Y W-135 conjugate
Indications Alopecia areata
Focus Adverse reactions; Pharmacodynamics; Registrational
Acronyms ALLEGRO-LT
Sponsors Pfizer

Most Recent Events

01 Jun 2025 Results assessing ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss published in the Journal of the European Academy of Dermatology and Venereology
03 Jul 2024 Planned End Date changed from 4 Feb 2026 to 23 Jan 2026.
21 Dec 2023 Planned End Date changed from 3 Feb 2026 to 4 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com